TRex Bio, Inc. (TRXB)Healthcare | Biotechnology | South San Francisco, United States | NasdaqGS
14.00 USD
After hours: 14.43 +0.43 (3.100%) ⇧ (Oct. 9, 2026, 6:26 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 9:56 a.m. EDT
The short-term outlook is severely bearish due to a catastrophic cash burn rate of nearly $46 million annually against a mere $91 million cash reserve, creating an imminent liquidity crisis that likely necessitates dilutive capital raises or asset sales within months. The long-term investment case is equally weak because the company lacks any revenue history, growth trajectory, or operational track record; without a proven business model to generate cash flow, the current valuation represents a speculative gamble on future success rather than a sound investment in a viable enterprise. Furthermore, there is no dividend income to offset these fundamental risks, making this a high-risk speculative vehicle unsuitable for investors seeking capital preservation or income. |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.225 |
| Market Cap | 384,239,552 |
| Website | https://trex.bio |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.0 |
| Address1 | 269 East Grand Avenue |
| Address2 | Suite 300 |
| All Time High | 15.5 |
| All Time Low | 13.5 |
| Average Daily Volume10 Day | 1,257,000 |
| Average Daily Volume3 Month | 1,257,000 |
| Average Volume | 1,257,000 |
| Average Volume10Days | 1,257,000 |
| City | South San Francisco |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 14.0 |
| Current Ratio | 12.181 |
| Custom Price Alert Confidence | HIGH |
| Day High | 15.5 |
| Day Low | 13.5 |
| Debt To Equity | 0.225 |
| Ebitda | -49,941,500 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -3.8 |
| Enterprise Value | 189,759,024 |
| Eps Trailing Twelve Months | -2.47 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 14.0 |
| Fifty Day Average Change | 0.0 |
| Fifty Day Average Change Percent | 0.0 |
| Fifty Two Week Change Percent | 0.0 |
| Fifty Two Week High | 15.5 |
| Fifty Two Week High Change | -1.5 |
| Fifty Two Week High Change Percent | -0.09677419 |
| Fifty Two Week Low | 13.5 |
| Fifty Two Week Low Change | 0.5 |
| Fifty Two Week Low Change Percent | 0.037037037 |
| Fifty Two Week Range | 13.5 - 15.5 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,791,552,600,000 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 60 |
| Fullday Change | 0.43400002 |
| Fullday Change Percent | 3.1000001 |
| Fullday Price | 14.0 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Implied Shares Outstanding | 27,445,682 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,026-10-09 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | TRex Bio, Inc. operates as a clinical-stage biopharmaceutical company that engages in discovery and development of immunoregulatory medicines. It develops medicines that helps restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. The company's product pipeline focuses on augmenting tissue Tregs to address critical treatment gaps and offers TRB-061, a phase 1 trial TNFR2-selective agonist designed to activate and expand effector Tregs in the tissue and restore immune balance in inflammatory diseases. TRB-061 is in clinical development for moderate-to-severe atopic dermatitis (AD). It is also developing TRB-071, an investigational CD30 agonist designed to both augment tissue Tregs and block an immune system inflammatory pathway. The company was incorporated in 2018 and is based in South San Francisco, California. |
| Long Name | TRex Bio, Inc. |
| Market | us_market |
| Market Cap | 384,239,552 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_626251120 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -46,392,000 |
| New Listing Date | 2,026-10-09 |
| Next Fiscal Year End | 1,798,675,200 |
| Open | 13.5 |
| Operating Cashflow | -46,251,000 |
| Operating Margins | 0.0 |
| Phone | (650) 567-5582 |
| Post Market Change | 0.43400002 |
| Post Market Change Percent | 3.1000001 |
| Post Market Price | 14.434 |
| Post Market Time | 1,791,584,811 |
| Previous Close | 14.0 |
| Price Hint | 2 |
| Profit Margins | 0.0 |
| Quick Ratio | 11.867 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0 |
| Regular Market Change Percent | 0.0 |
| Regular Market Day High | 15.5 |
| Regular Market Day Low | 13.5 |
| Regular Market Day Range | 13.5 - 15.5 |
| Regular Market Open | 13.5 |
| Regular Market Previous Close | 14.0 |
| Regular Market Price | 14.0 |
| Regular Market Time | 1,791,576,000 |
| Regular Market Volume | 1,258,340 |
| Sand P52 Week Change | 0.17383456 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 27,445,682 |
| Short Name | TRex Bio, Inc. |
| Source Interval | 15 |
| State | CA |
| Symbol | TRXB |
| Total Cash | 90,854,000 |
| Total Cash Per Share | 19.04 |
| Total Debt | 197,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.47 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 14.0 |
| Two Hundred Day Average Change | 0.0 |
| Two Hundred Day Average Change Percent | 0.0 |
| Type Disp | Equity |
| Volume | 1,258,340 |
| Website | https://trex.bio |
| Zip | 94,080 |